NaturalAntibody
NaturalAntibody provides a data-driven platform leveraging machine learning and comprehensive antibody databases to accelerate therapeutic antibody discovery and development. Their solutions offer features like antibody sequence analysis for developability predictions, language model-based mutational suggestions, and hit picking with multiple clustering methods. The platform also includes structural modeling and antibody-antigen docking for lead optimization. NaturalAntibody aims to streamline the drug discovery process by providing researchers with advanced computational tools and curated data, enabling faster and safer development of novel biotherapeutics.
NaturalAntibody
NaturalAntibody provides a data-driven platform leveraging machine learning and comprehensive antibody databases to accelerate therapeutic antibody discovery and development. Their solutions offer features like antibody sequence analysis for developability predictions, language model-based mutational suggestions, and hit picking with multiple clustering methods. The platform also includes structural modeling and antibody-antigen docking for lead optimization. NaturalAntibody aims to streamline the drug discovery process by providing researchers with advanced computational tools and curated data, enabling faster and safer development of novel biotherapeutics.
TL;DR
Founded: 2020
Headquarters: Szczecin, Poland
Product: AI-driven antibody analytics platform and antibody databases
Total funding reported: USD 8,773,071 (includes grants and rounds listed)
Founders: Konrad Krawczyk; Michał Krawczyk
Company Overview
Problem Domain
Therapeutic antibody discovery and development; computational antibody design and developability prediction.
Founded
2020
Industry
Biotechnology
Tech Stack
Funding Track Record
1700000
Non-equity research grant announced to expand AI platform (National Centre for Research and Development).
750000
Pre-seed round reported.
3100000
Dealroom entry lists a Sep 2025 grant of PLN 3.1M.
Investor Signal
“WP2 Investments and Tar Heel Capital Pathfinder cited as institutional investors”